論文

2022 英文

TITLE & JOURNAL/AUTHORS

• Soluble programmed cell death-1 predicts hepatocellular carcinoma development during nucleoside analogue treatment
  著者名：Kozuka R, Enomoto M, Dong MP, Hai H, Thuy LTT, Odagiri N, Yoshida K, Kotani K, Motoyama H, Kawamura E, Hagihara A, Fujii H, Uchida-Kobayashi S, Tamori A, Kawada N.
  出版物名：Sci Rep. 2022 Jan 7;12(1):105. doi: 10.1038/s41598-021-03706-w.
• Lifestyle changes during the coronavirus disease 2019 pandemic impact metabolic dysfunction-associated fatty liver disease
  著者名：Fujii H, Nakamura N, Fukumoto S, Kimura T, Nakano A, Nadatani Y, Tauchi Y, Nishii Y, Takashima S, Kamada Y, Watanabe T, Kawada N.
  出版物名：Liver Int. 2022 Jan 7. doi: 10.1111/liv.15158. Online ahead of print.
• Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-based Cohort Study
  著者名：Fujii H, Iwaki M, Hayashi H, Toyoda H, Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Yamamura S, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Kawada N, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD).
  出版物名：Clin Gastroenterol Hepatol. 2022 Jan 17;S1542-3565(22)00008-8. doi: 10.1016/j.cgh.2022.01.002. Online ahead of print.
• Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis
  著者名：Tahata Y, Hikita H, Mochida S, Enomoto N, Kawada N, Kurosaki M, Ido A, Miki D, Yoshiji H, Takikawa Y, Sakamori R, Hiasa Y, Nakao K, Kato N, Ueno Y, Yatsuhashi H, Itoh Y, Tateishi R, Suda G, Takami T, Nakamoto Y, Asahina Y, Matsuura K, Yamashita T, Kanto T, Akuta N, Terai S, Shimizu M, Sobue S, Miyaki T, Moriuchi A, Yamada R, Kodama T, Tatsumi T, Yamada T, Takehara T.
  出版物名：J Gastroenterol. 2022 Feb;57(2):120-132. doi: 10.1007/s00535-021-01845-5. Epub 2022 Jan 20.
• Hepatocelluar Carcinoma Risk in Advanced Fibrosis After Sustained Virologic Response: When Can We Safely Stop Hepatocellular Carcinoma Surveillance?
  著者名：Enomoto M, Vutien P, Kawada N.
  出版物名：Hepatol Commun. 2022 Mar;6(3):445-447. doi: 10.1002/hep4.1864. Editorial
• Capacity of extracellular globins to reduce liver fibrosis via scavenging reactive oxygen species and promoting MMP-1 secretion
  著者名：Hieu VN, Thuy LTT, Hai H, Dat NQ, Hoang DV, Hanh NV, Phuong DM, Hoang TH, Sawai H, Shiro Y, Sato-Matsubara M, Oikawa D, Tokunaga F, Yoshizato K, Kawada N.
  出版物名：Redox Biol. 2022 Mar 19;52:102286. doi: 10.1016/j.redox.2022.102286. Online ahead of print.
• Multiple cancer type classification by small RNA expression profiles with plasma samples from multiple facilities
  著者名：Suzuki K, Igata H, Abe M, Yamamoto Y; small RNA based cancer classification project.
  出版物名：Cancer Sci. 2022 Feb 26. doi: 10.1111/cas.15309. Online ahead of print.
• Serum miR-192-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis B
  著者名：Nagura Y, Matsuura K, Iio E, Fujita K, Inoue T, Matsumoto A, Tanaka E, Nishiguchi S, Kang JH, Matsui T, Enomoto M, Ikeda H, Watanabe T, Okuse C, Tsuge M, Atsukawa M, Tateyama M, Kataoka H, Tanaka Y.
  出版物名：PLoS One. 2022 Feb 14;17(2):e0263844. doi: 10.1371/journal.pone.0263844. eCollection 2022.
• Distinct responsiveness to rifaximin in patients with hepatic encephalopathy depends on functional gut microbial species
  著者名：Yukawa-Muto Y, Kamiya T, Fujii H, Mori H, Toyoda A, Sato I, Konishi Y, Hirayama A, Hara E, Fukuda S, Kawada N, Ohtani N.
  出版物名：Hepatol Commun. 2022 Apr 16. doi: 10.1002/hep4.1954. Online ahead of print.
• Clinical evaluation of [ 18 F]pitavastatin for quantitative analysis of hepatobiliary transporter activity
  著者名：Nakaoka T, Kaneko KI, Irie S, Mawatari A, Igesaka A, Uetake Y, Ochiai H, Niwa T, Yamano E, Wada Y, Tanaka M, Kotani K, Kawahata H, Kawabe J, Miki Y, Doi H, Hosoya T, Kazuya M, Kusuhara H, Sugiyama Y, Watanabe Y.
  出版物名：Drug Metab Pharmacokinet. 2022 Feb 1;44:100449. doi: 10.1016/j.dmpk.2022.100449. Online ahead of print.
• Cytoglobin attenuates pancreatic cancer growth via scavenging reactive oxygen species
  著者名：Hoang DV, Thuy LTT, Hai H, Hieu VN, Kimura K, Oikawa D, Ikura Y, Dat NQ, Hoang TH, Sato-Matsubara M, Dong MP, Hanh NV, Uchida-Kobayashi S, Tokunaga F, Kubo S, Ohtani N, Yoshizato K, Kawada N.
  出版物名：Oncogenesis. 2022 May 3;11(1):23. doi: 10.1038/s41389-022-00389-4.
• Gasdermin D-mediated release of IL-33 from senescent hepatic stellate cells promotes obesity-associated hepatocellular carcinoma
  著者名：Yamagishi R, Kamachi F, Nakamura M, Yamazaki S, Kamiya T, Takasugi M, Cheng Y, Nonaka Y, Yukawa-Muto Y, Thuy LTT, Harada Y, Arai T, Loo TM, Yoshimoto S, Ando T, Nakajima M, Taguchi H, Ishikawa T, Akiba H, Miyake S, Kubo M, Iwakura Y, Fukuda S, Chen WY, Kawada N, Rudensky A, Nakae S, Hara E, Ohtani N.
  出版物名：Sci Immunol. 2022 Jun 24;7(72):eabl7209. doi: 10.1126/sciimmunol.abl7209. Epub 2022 Jun 24.
• Cloaking the ACE2 receptor with salivary cationic proteins inhibits SARS-CoV-2 entry
  著者名：Yoshizato K, Taira T, Sato-Matsubara M, Sekiguchi S, Yabunaka Y, Kira Y, Ohashi T, Daikoku A, Ofusa K, Kadono C, Oikawa D, Matsubara T, Nakagama Y, Kido Y, Tokunaga F, Ikeda K, Kaneko A, Kawada N.
  出版物名：J Biochem. 2022 Sep 30;172(4):205-216. doi: 10.1093/jb/mvac054.
• Non-heat-stressed Method to Isolate Hepatic Stellate Cells From Highly Steatotic Tumor-bearing Liver Using CD49a
  著者名：Cheng Y, Yamagishi R, Nonaka Y, Sato-Matsubara M, Kawada N, Ohtani N.
  出版物名：Cell Mol Gastroenterol Hepatol. 2022;14(4):964-966.e9. doi: 10.1016/j.jcmgh.2022.07.006. Epub 2022 Jul 19.
• Soluble Immune Checkpoint Protein CD27 Is a Novel Prognostic Biomarker of Hepatocellular Carcinoma Development in Hepatitis C Virus-Sustained Virological Response Patients
  著者名：Dong MP, Thuy LTT, Hoang DV, Hai H, Hoang TH, Sato-Matsubara M, Hieu VN, Daikoku A, Hanh NV, Urushima H, Dat NQ, Uchida-Kobayashi S, Enomoto M, Ohtani N, Tamori A, Kawada N.
  出版物名：Am J Pathol. 2022 Oct;192(10):1379-1396. doi: 10.1016/j.ajpath.2022.07.003. Epub 2022 Aug 11.
• Nitric oxide derived from cytoglobin-deficient hepatic stellate cells causes suppression of cytochrome c oxidase activity in hepatocytes
  著者名：Okina Y, Sato-Matsubara M, Kido Y, Urushima H, Daikoku A, Kadono C, Nakagama Y, Nitahara Y, Hoang TH, Thuy LTT, Matsubara T, Ohtani N, Ikeda K, Yoshizato K, Kawada N.
  出版物名：Antioxid Redox Signal. 2022 Sep 16. doi: 10.1089/ars.2021.0279. Online ahead of print.
• Suppression of intrahepatic cholangiocarcinoma cell growth by SKI via upregulation of the CDK inhibitor p21
  著者名：Kawamura E, Matsubara T, Daikoku A, Deguchi S, Kinoshita M, Yuasa H, Urushima H, Odagiri N, Motoyama H, Kotani K, Kozuka R, Hagihara A, Fujii H, Uchida-Kobayashi S, Tanaka S, Takemura S, Iwaisako K, Enomoto M, Taguchi YH, Tamori A, Kubo S, Ikeda K, Kawada N.
  出版物名：FEBS Open Bio. 2022 Sep 17. doi: 10.1002/2211-5463.13489. Online ahead of print.
• Cancer cells produce liver metastasis via gap formation in sinusoidal endothelial cells through proinflammatory paracrine mechanisms
  著者名：Huu Hoang T, Sato-Matsubara M, Yuasa H, Matsubara T, Thuy LTT, Ikenaga H, Phuong DM, Hanh NV, Hieu VN, Hoang DV, Hai H, Okina Y, Enomoto M, Tamori A, Daikoku A, Urushima H, Ikeda K, Dat NQ, Yasui Y, Shinkawa H, Kubo S, Yamagishi R, Ohtani N, Yoshizato K, Gracia-Sancho J, Kawada N.
  出版物名：Sci Adv. 2022 Sep 30;8(39):eabo5525. doi: 10.1126/sciadv.abo5525. Epub 2022 Sep 28.
• Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort
  著者名：Hsu YC, Jun DW, Peng CY, Yeh ML, Trinh H, Wong GL, Kim SE, Chen CH, Oh H, Lin CH, Trinh L, Wong VW, Yoon E, Ahn SB, Huang D, Cho YK, Jeong JY, Jeong SW, Kim HS, Xie Q, Liu L, Riveiro-Barciela M, Tsai PC, Accarino EV, Toyoda H, Enomoto M, Preda C, Marciano S, Hoang J, Huang CF, Kozuka R, Yasuda S, Istratescu D, Lee DH, Su JY, Huang YT, Huang JF, Dai CY, Chuang WL, Yuen MF, Gadano A, Cheung R, Lim SG, Buti M, Yu ML, Nguyen MH.
  出版物名：Hepatol Int. 2022 Sep 7. doi: 10.1007/s12072-022-10411-x. Online ahead of print.
• Prolonged extrapyramidal symptoms induced by long-term, intermittent administration of low-dose olanzapine along with metoclopramide for emesis: A case report
  著者名：Shoko Sakamoto, Yasuhiko Deguchi, Sawako Uchida, Yoshiaki Itoh, Koki Inoue.
  出版物名：Neuropsychopharmacol Rep. 2022 Sep;42(3):380-383. doi: 10.1002/npr2.12277. Epub 2022 Jun 18. Case Reports
• Serum Mac-2 binding protein level predicts the development of liver-related events and colorectal cancer in patients with NAFLD
  著者名：Kamada Y, Nakahara T, Munekage K, Fujii H, Sawai Y, Doi Y, Ono M, Hyogo H, Sumida Y, Morishita K, Asuka T, Ouchida T, Imai Y, Miyoshi E; Japan Study Group of NAFLD.
  出版物名：Hepatol Commun. 2022 Jul;6(7):1527-1536. doi: 10.1002/hep4.1934. Epub 2022 Apr 27.
• Global multi-stakeholder endorsement of the MAFLD definition
  著者名：Méndez-Sánchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, Sarin SK, Fabrellas N, Zelber-Sagi S, Fan JG, Shiha G, Targher G, Zheng MH, Chan WK, Vinker S, Kawaguchi T, Castera L, Yilmaz Y, Korenjak M, Spearman CW, Ungan M, Palmer M, El-Shabrawi M, Gruss HJ, Dufour JF, Dhawan A, Wedemeyer H, George J, Valenti L, Fouad Y, Romero-Gomez M, Eslam M; Global multi-stakeholder consensus on the redefinition of fatty liver disease.
  出版物名：Lancet Gastroenterol Hepatol. 2022 May;7(5):388-390. doi: 10.1016/S2468-1253(22)00062-0. Epub 2022 Mar 3.
• Age-dependent effects of diabetes and obesity on liver-related events in non-alcoholic fatty liver disease: Subanalysis of CLIONE in Asia
  著者名：Seko Y, Kawanaka M, Fujii H, Iwaki M, Hayashi H, Toyoda H, Oeda S, Hyogo H, Morishita A, Munekage K, Kawata K, Yamamura S, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Okanoue T, Itoh Y, Nakajima A; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD).
  出版物名：J Gastroenterol Hepatol. 2022 Oct 5. doi: 10.1111/jgh.16019. Online ahead of print.
• Prognostic Nutrition Index as an Indicator of Therapeutic Response to Lenvatinib Therapy in Hepatocellular Carcinoma
  著者名：Shibano M, Takahashi K, Takahashi M, Uchida-Kobayashi S, Kawada N, Nakamura Y, Otori T, Nagayama K.
  出版物名：Anticancer Res. 2022 Dec;42(12):6019-6026. doi: 10.21873/anticanres.16113.
• Efficacy of rechallenge transcatheter arterial chemoembolization after lenvatinib treatment for advanced hepatocellular carcinoma
  著者名：Uchida-Kobayashi S, Kageyama K, Takemura S, Matsumoto K, Odagiri N, Jogo A, Kotani K, Kozuka R, Motoyama H, Kawamura E, Hagihara A, Yamamoto A, Fujii H, Tanaka S, Enomoto M, Tamori A, Miki Y, Kubo S, Kawada N.
  出版物名：JGH Open. 2022 Sep 21;6(11):754-762. doi: 10.1002/jgh3.12819. eCollection 2022 Nov.
• SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: an expert review by the JANIT Forum
  著者名：Kamada Y, Nakamura T, Isobe S, Hosono K, Suama Y, Ohtakaki Y, Nauchi A, Yasuda N, Mitsuta S, Miura K, Yamamoto T, Hosono T, Yoshida A, Kawanishi I, Fukushima H, Kinoshita M, Umeda A, Kinoshita Y, Fukami K, Miyawaki T, Fujii H, Yoshida Y, Kawanaka M, Hyogo H, Morishita A, Hayashi H, Tobita H, Tomita K, Ikegami T, Takahashi H, Yoneda M, Jun DW, Sumida Y, Okanoue T, Nakajima A; JANIT Forum.
  出版物名：J Gastroenterol. 2022 Dec 5;1-19. doi: 10.1007/s00535-022-01932-1. Online ahead of print. Review
• Prognostic Nutrition Index as an Indicator of Therapeutic Response to Lenvatinib Therapy in Hepatocellular Carcinoma
  著者名：Shibano M, Takahashi K, Takahashi M, Uchida-Kobayashi S, Kawada N, Nakamura Y, Otori T, Nagayama K.
  出版物名：Anticancer Res. 2022 Dec;42(12):6019-6026. doi: 10.21873/anticanres.16113.
• Risk Factors for Liver-Related and Non-Liver-Related Mortality following a Sustained Virological Response after Direct-Acting Antiviral Treatment for Hepatitis C Virus Infection in a Real-World Cohort
  著者名：Kozuka R, Tamori A, Enomoto M, Yukawa-Muto Y, Odagiri N, Kotani K, Motoyama H, Kawamura E, Hagihara A, Fujii H, Uchida-Kobayashi S, Kawada N.
  出版物名：J Viral Hepat. 2022 in press.

2022 和文

タイトル・著者

• 【肝硬変症の診断治療の最新知見】肝線維化進展の分子機序、血中肝線維化マーカー（解説/特集）
  著者名：小田桐 直志，河田 則文
  出版物名：日本内科学会雑誌（0021-5384）111巻1号 Page15-21（2022.01）
• 【Intermediate stage HCCに対するTACE】 TACEと分子標的薬の併用療法の臨床成績（総説）
  著者名：影山 健，打田 佐和子，山本 晃，城後 篤志，寒川 悦次
  出版物名：日本インターベンショナルラジオロジー学会雑誌（1340-4520） 36巻3号　Page254-260（2022.8）
• 糖尿病と脂肪肝　　代謝異常関連脂肪肝MAFLDとは何か（解説）
  著者名：藤井 英樹
  出版物名：大阪府内科医会会誌（1881-669X） 31巻1号Page34-39（2022.06）
• 学会・家事・SNSに関するアンケート調査結果 肝臓学会会員285名の回答（原著論文）
  著者名：藤井 英樹，田中 聡司，山田 涼子，野村 貴子，恵莊 裕嗣，石井 隆道，飯島 尋子，日本肝臓学会キャリア支援・ダイバーシティ推進委員西部会ワーキンググループ
  出版物名：肝臓（0451-4203）63巻6号　Page259-267（2022.06）
• 【アルコールと肝疾患　up to date】 アルコール性肝疾患と非アルコール性肝疾患のクロストーク（総説）
  著者名：藤井 英樹
  出版物名：日本消化器病学会雑誌（0446-6586）119巻1号　Page36-46（2022.01）
• 【肝障害の相談を受けたとき-最近よくみる症例の特徴-】 非アルコール性脂肪性肝疾患の診断と治療（解説）
  著者名：角田 圭雄，石破 博， 藤井 英樹，小野 正文，鎌田 佳宏，高橋 宏和，川口 巧，中島 淳， 伊藤 義人，岡上 武
  出版物名：肝臓クリニカルアップデート（2189-4469）7巻2号　Page171-178（2022.04）
• 【ウイルス肝炎制御時代の肝発癌】 ウイルス肝炎制御をめぐる疫学と最新動向 わが国におけるNAFLD/NASHの疫学（解説）
  著者名：角田 圭雄，藤井 英樹， 高橋 宏和，鎌田 佳宏，川口 巧，中島 淳
  出版物名：臨床消化器内科（0911-601X）37巻8号 Page80-887（2022.07）

論文一覧 バックナンバー

• 2021年
• 2020年
• 2019年
• 2018年
• 2017年
• 2016年
• 2015年
• 2014年
• 2013年
• 2012年
• 2011年
• 2010年
• 2009年
• 2008年
• 2007年
• 2006年
• 2005年